Collaborative Agreements	6 Months Ended
Jun. 30, 2020
Collaborative Agreements [Abstract]
COLLABORATIVE AGREEMENTS	NOTE 8 – COLLABORATIVE AGREEMENTS During 2019, the Company was awarded a $1,000,000 grant from the Alzheimer's Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer's disease. The endowment was awarded under the Part the Cloud to RESCUE grant. During the six months ending June 30, 2020 and 2019, the Company received $0 and $600,000, respectively, related to the grant, which the Company recorded as a reduction of research and development expense. As of June 30, 2020, the Company has received $850,000 of cash proceeds pursuant to this grant. During July 2020, the Company received the final payment tranche of $150,000 from the Alzheimer's Association. During the six months ended June 30, 2020, the Company was awarded a $500,000 grant from the Amyotrophic Lateral Sclerosis (ALS) Association to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo. During the six months ended June 30, 2020, the Company received $300,000 of cash proceeds pursuant to this grant which the Company recorded as deferred liabilities on the balance sheet as of June 30, 2020. The Company expects to incur costs in connection with the ALS research beginning in the third quarter of 2020, of which the expenses will be offset by the grant. In the event costs incurred for the ALS research are less than the grant, the remainder would be returned to the ALS Association.

Collaborative Agreements

6 Months Ended

Jun. 30, 2020

NOTE 8 – COLLABORATIVE AGREEMENTS

During 2019, the Company was awarded a $1,000,000 grant from the Alzheimer's Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer's disease. The endowment was awarded under the Part the Cloud to RESCUE grant. During the six months ending June 30, 2020 and 2019, the Company received $0 and $600,000, respectively, related to the grant, which the Company recorded as a reduction of research and development expense. As of June 30, 2020, the Company has received $850,000 of cash proceeds pursuant to this grant. During July 2020, the Company received the final payment tranche of $150,000 from the Alzheimer's Association.

During the six months ended June 30, 2020, the Company was awarded a $500,000 grant from the Amyotrophic Lateral Sclerosis (ALS) Association to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo. During the six months ended June 30, 2020, the Company received $300,000 of cash proceeds pursuant to this grant which the Company recorded as deferred liabilities on the balance sheet as of June 30, 2020. The Company expects to incur costs in connection with the ALS research beginning in the third quarter of 2020, of which the expenses will be offset by the grant. In the event costs incurred for the ALS research are less than the grant, the remainder would be returned to the ALS Association.